First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors [0.03%]
一项在晚期实体瘤患者中评估sitravatinib的首次人体I/Ib期研究
Todd Bauer,Byong Chul Cho,Rebecca Heist et al.
Todd Bauer et al.
Sitravatinib (MGCD516), a spectrum-selective receptor tyrosine kinase inhibitor targeting TAM (TYRO3, AXL, MERTK) and split kinase family receptors, has demonstrated preclinical anti-tumor activity and modulation of tumor microenvironment. ...
Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trial [0.03%]
硫脲和顺铂治疗难治性生殖细胞肿瘤二期临床试验(GCT-SK-006二期临床试验)
M Mego,D Svetlovska,De Angelis V et al.
M Mego et al.
Background: Multiple relapsed/refractory germ cell tumor (GCT) patients have extremely poor prognosis. Cisplatin resistant testicular GCTs overexpress aldehyde-dehydrogenase (ALDH) isoforms and inhibition of ALDH activity...
MY11 exerts antitumor effects through activation of the NF-κB/PUMA signaling pathway in breast cancer [0.03%]
MY11通过激活NF-κB/PUMA信号通路在乳腺癌中发挥抗肿瘤作用
Qun Ye,Ziwei Jiang,Ying Xie et al.
Qun Ye et al.
Breast cancer is the most common malignancy in women worldwide, and the discovery of new effective breast cancer therapies with lower toxicity is still needed. We screened a series of chalcone derivatives and found that MY11 ((E)-1-(2-hydro...
A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors [0.03%]
一项II期研究：评估ASP1650治疗复发/难治性精原细胞瘤男性的安全性和有效性
Nabil Adra,David J Vaughn,Lawrence H Einhorn et al.
Nabil Adra et al.
Claudin6(CLDN6) is a tight junction protein of claudin-tetraspanin family and is of the earliest molecules expressed in embryonic epithelium. CLDN6 is frequently aberrantly expressed in testicular germ-cell tumors(GCT). ASP1650 is a chimeri...
Genetic variations in the ATP-binding cassette transporter ABCC10 are associated with neutropenia in Japanese patients with lung cancer treated with nanoparticle albumin-bound paclitaxel [0.03%]
日籍肺癌症患者接受白蛋白结合型紫杉醇治疗时ABCC10基因多态性与中性粒细胞减少症相关性研究
Minoru Horiuchi,Takehiro Uemura,Tetsuya Oguri et al.
Minoru Horiuchi et al.
ABCC10/MRP7, an ATP-binding cassette (ABC) transporter, has been implicated in the extracellular transport of taxanes. Our group reported that the ABCC10 single nucleotide polymorphism (SNPs), rs2125739, influences docetaxel cytotoxicity in...
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer [0.03%]
阿替利珠单抗联合卡铂和依托泊苷治疗后用于复发小细胞肺癌患者的氨鲁比星单药疗效和安全性研究
Hisao Imai,Yoshiaki Nagai,Hiroyuki Minemura et al.
Hisao Imai et al.
This study examined the activity and safety of amrubicin monotherapy among relapsed small-cell lung cancer (SCLC) patients who had previously been treated with atezolizumab plus carboplatin and etoposide (AteCE). This retrospective study ev...
A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer [0.03%]
结直肠癌的微生物群组成及宿主驱动基因突变的全面分析
Danping Yuan,Yong Tao,Haoyi Wang et al.
Danping Yuan et al.
Studies of both, microbiota and target therapy associated with gene mutations in colorectal cancer, (CRC) have attracted increasing attention. However, only a few of them analyzed the combined effects on CRC. we analyzed differences in inte...
Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma [0.03%]
克唑替尼治疗失败后艾乐昔替尼治疗引起的肺腺癌病人肺内肉芽肿炎症反应病例报告及文献复习
Juanyan Liao,Hui Guan,Min Yu et al.
Juanyan Liao et al.
Ceritinib is a new anaplastic lymphoma kinase (ALK) inhibitor that has shown greater potency in patients with advanced ALK-rearranged non-small cell lung cancer, including those who had disease progression in crizotinib treatment. Here we r...
The efficacy of transarterial chemoembolization in downstaging unresectable hepatocellular carcinoma to curative therapy: a predicted regression model [0.03%]
经导管动脉化疗栓塞将不可切除的肝细胞癌缩小至治愈性治疗的效果预测模型研究
Haomin Lin,Bin Luo,Fangyi Peng et al.
Haomin Lin et al.
Patients with hepatocellular carcinoma (HCC) outside Milan criteria (MC) may be candidates for curative therapy after successful downstaging. We aimed to identify the predictors of successful downstaging of unresectable HCC in patient by tr...
ZL-n-91, a specific Phosphodiesterase-4 inhibitor, suppresses the growth of triple-negative breast cancer [0.03%]
新型磷二酯酶4抑制剂ZL-n-91通过调控巨噬细胞功能抑制三阴性乳腺癌生长转移
Longming Liang,Hansi Chen,Ping Mao et al.
Longming Liang et al.
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that frequently develops resistance to chemotherapy. A new approach to treating TNBC is required to improve patient survival. Phosphodiesterase-4 (PDE4) is an en...